easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Bank of America Upgrades T-Mobile to Buy, Says LEO Satellite Fears Are Overdone 
Citi Raises TSMC Price Target as AI Chip Demand Strengthens Growth Outlook 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
DOJ Seeks Dismissal of Gautam Adani Bribery Case, Citing Foreign Scope 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Hanmi Pharmaceutical will get US$10 million from Merck Sharp & Dohme (MSD) as initial contract payment in an $860 million exclusive licensing deal for the development, manufacture, and commercialization of its liver treatment candidate material efinopegdutide.
Under the deal, Hamni will be getting royalty payments from MSD with the development of the efinopegdutide.
However, the overall payment MSD will give Hanmi is contingent on regulatory permission and the drug's success in the market.
Efinopegdutide is for treating nonalcoholic steatohepatitis (NASH), a condition where the liver suffers inflammation and damage due to excess fat in the organ.
The South Korean pharmaceutical firm claimed findings from the latest phase 2 studies have provided compelling clinical evidence that the material can be used on people with NASH.
Efinopegdutide was originally developed for insulin secretion and obesity control, in cooperation with Janssen Pharmaceutica.
A 2015 deal to develop and market the drug through due to shortfalls related to blood sugar level control.
